The present invention provides for the integration of drug dispersion methods into a drug or medicine delivery system. The drug dispersion methods used include shear (e.g., air across a drug, with or without a gas assist), capillary flow or a venturi effect, mechanical means such as spinning, vibration, or impaction, and turbulence (e.g., using mesh screens, or restrictions in the air path). These methods of drug dispersion allow for all of the drug in the system to be released, allowing control of the dosage size. These methods also provide for drug metering, fluidization, entrainment, deaggragation and deagglomeration. The present invention also provides for the integration of a drug sealing system into the device. The drug sealing system provides a way of blocking the migration of drug from one area of the package to another. The drug seal system can also provide a method of tightly containing the drug until the package is opened, of directing airflow through the package and of managing and containing the drug during the package/device manufacturing process.

Exemplary embodiments include dry powder inhalers (DPIs) and patient interfaces which improve delivery of aerosols to patients, especially children.

The present invention relates to an inhaler device for delivering a dose of medicament in dry powder form from a container to a patient in need thereof. The inhaler comprises a swirl chamber in which particles of the medicament entrained in an airflow swirl upon inhalation thereby breaking up the agglomerates into finest dispersed powder.

An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. The capsule cavity has a length extending along the longitudinal axis. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. A capsule is disposed within the capsule cavity and has a capsule length. The capsule length is in a range from about 25% to about 99% of the cavity length, or about 50% to about 95% of the cavity length, or about 70% to about 90% of the cavity length, or from about 75% to about 85% of the cavity length, or about 80% of the cavity length.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

Devices, systems, and methods are provided for adherence monitoring and patient interaction. In general, the devices, systems, and methods can facilitate a patient's adherence to a medication schedule and can facilitate monitoring and tracking of the patient's adherence to the medication schedule. In one embodiment, a medical accessory such as a cap is provided that can be configured to attach to existing medication dispensers, such as asthma inhalers, or to be integrated into a custom-made medication dispenser. The accessory can be configured to provide a notification to the patient when medication is due. The accessory can be configured to detect usage of the dispenser. The accessory can be configured to provide data regarding dispensing of the medication to an external device. The data can be analyzed and provided for visualization on a user interface.

The methods described herein provide improvements to the measurement of dose content uniformity of inhaler and nasal devices. The methods involve analyzing and measuring a spray pattern of an emitted spray from an inhaler or nasal device. The spray pattern may be used to determine the dose content uniformity of an inhaler or nasal device.

The invention relates to a fluid reservoir (2) for an aerosol generator (50), the fluid reservoir (2) comprising a fluid chamber (4) for receiving a fluid (6), an opening (8) for guiding the fluid (6) received in the fluid chamber (4) outside the fluid chamber (4), and a collar portion (10) surrounding the opening (8) and extending into the fluid chamber (4). A first portion (12) of the fluid chamber (4) extends along the length of the collar portion (10) in a height direction (H) of the fluid chamber (4), A second portion (14) of the fluid chamber (4) is arranged adjacent to the first portion (12) in the height direction (H) of the fluid chamber (4). A lateral extension of the first portion (12) in the directions perpendicular to the height direction (H) of the fluid chamber (4) is smaller than a lateral extension of the second portion (14) in the directions perpendicular to the height direction (H) of the fluid chamber (4). Further, the invention relates to a fluid reservoir (2′) for an aerosol generator (50), the fluid reservoir (2′) comprising a fluid chamber (4′) for receiving a fluid (6′), an opening (8′) for guiding the fluid (6′) received in the fluid chamber (4′) outside the fluid chamber (4′), a recess (9) arranged at least partly below the opening (8!) in a height direction (H) of the fluid chamber (4′), and a cover member (30′) which releasably or permanently seals the recess (9). Moreover, the invention relates to an aerosol generator (50) comprising the fluid reservoir (2, 2′).

The present invention provides a particulate delivery device with an automatic activation mechanism that pierces or cuts a composition capsule when a cap is removed. The cap cannot be replaced once the device is activated for use. The device allows for gas flow through the device from a gas inlet to a gas outlet through a composition receptacle and dispersion chamber to deliver particulate to the airway of a subject.

A dry powder inhaler (1) has a chamber (12) for housing a capsule and an inhalation channel (22), the chamber (12) is shaped in order to determine an agitated motion of the capsule in the chamber (12) during an inhalation of a user, the inhaler (1) comprises a capsule-piercing mechanism (30) arranged to pierce a capsule in the chamber (12) and a monitoring system (40) comprising an accelerometer (42) arranged on a printed circuit board (48) in order to measure mechanical oscillations determined at least by the agitated motion and by a flow of air through the chamber (12) and/or inhalation channel (22); a detection unit (44) arranged to detect an activation of the capsule-piercing mechanism (30); and an electronic processing unit (46) configured to receive signals from the detection unit (44) and from the accelerometer (42). Reception of a signal from the detection unit (44) triggers processing of signals from the accelerometer (42) by the electronic processing unit (46) in order to generate inhalation data.